Meeting ReportOncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - Breast Cancer

Dose Escalation Study to Evaluate Safety, Dosimetry, and PD of the HER2-Directed Radioligand CAM-H2 in Patients With Advanced HER2+ Breast, Gastric, GEJ, and Other HER2+ Solid Tumors (trial ID: NCT04467515)

Josie Gayton, David Roberge, Rebecca Wong, Catalin Mihalcioiu, Daniel Juneau, Michael Yan, Neel Choudhary, Aruz Mesci, Judy Gabrys and Haytham Elgammal
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 242035;

Article Information

vol. 65 no. supplement 2 242035
Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online June 9, 2024.
Copyright & Usage 
© 2024

Author Information

  1. Josie Gayton1,
  2. David Roberge2,
  3. Rebecca Wong3,
  4. Catalin Mihalcioiu4,
  5. Daniel Juneau5,
  6. Michael Yan6,
  7. Neel Choudhary6,
  8. Aruz Mesci7,
  9. Judy Gabrys8 and
  10. Haytham Elgammal
  1. 1Precirix
  2. 2CHUM, Université de Montréal, Canada
  3. 3Radiation Medicine Program, Princess Margaret Cancer Center, University Health Network; Dept Radiation Oncology, University of Toronto
  4. 4McGill University, Montreal
  5. 5Université de Montréal, Montreal, QC, Canada
  6. 6Princess Margaret Cancer Centre, University of Toronto
  7. 7Radiation Medicine Program, Princess Margaret Cancer Center, University Health Network, University of Toronto
  8. 8Joint Department of Medical Imaging, UHN, Toronto, Canada

Statistics from Altmetric.com

Cited By...

Article usage

Article usage: June 2024 to September 2024

AbstractFullPdf
Jun 20244100
Jul 202418100
Aug 202415000
Sep 202410600
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 65, Issue supplement 2
June 1, 2024
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section